Myocardial Ischemia Clinical Trial
Official title:
Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT Trial)
Depression is commonly seen in patients with cardiovascular disorders. In recent studies it has been shown that mild to moderate depression symptoms were associated with increased likelihood of mental stress-induced myocardial ischemia (MSIMI), which is a risk factor of poor cardiac outcome. In this project, the investigators aim to assess the treatment of mental stress-induced myocardial ischemia in ischemic heart disease patients with mild to moderate depressive symptoms. This study is a six-week double-blind placebo controlled study to examine the effects of escitalopram on mental stress-induced myocardial ischemia. This study will look to show that patients with ischemic heart disease who are treated with escitalopram will exhibit a significant improvement of MSIMI at the end of week 6 compared to patients receiving placebo.
The goals of this project are to investigate the response of mental stress-induced
myocardial ischemia (MSIMI) to escitalopram, a selective serotonin reuptake inhibitor
(SSRI); to determine whether MSIMI will be reduced by the treatment, and whether the
modification of MSIMI is related to improvement of depression symptoms, and/or the reduction
of platelet aggregation, and/or the reduction of cardiovascular reactivity. This is a
randomized study using escitalopram versus placebo for stable ischemic heart disease
patients with MSIMI. This study will also explore the role of platelet activity in
occurrence with MSIMI and other characteristics of MSIMI, such as systolic and diastolic
function of the left ventricle during mental stress testing as compared to exercise testing.
The stress testing will be conducted at the Duke Cardiology Diagnostic Unit Laboratory.
Following a 20-minute calibration-rest period, participants will be asked to complete a
series of 3 mental stress tasks. There are 3 mental stress tasks to be used for this study,
i.e., (1) Mental arithmetic: during this test, patients will be asked to perform a series of
serial subtractions beginning at a given number which will be different for each repeated
test and will be chosen by the tester from a fixed list of various numbers, with
encouragement to perform calculations as quickly as possible; (2) Public speaking with anger
recall: during this test, patients will be asked to give a speech on a recent situation in
which they experienced anger to an audience of observers (two to three) after 1 minute of
preparation. Prior to the speech, subjects are told that their speech will be evaluated on
their description of the situation, as to what happened, what they thought, felt, what they
did, and what happened as a result. If they run out of things to say, the research tech will
prompt them with questions to elicit more content until the three minutes are up; (3) Mirror
trace: during this test, patients will be asked to outline, as quickly as possible, a star
from its reflection in a mirror. Each task will last 3 minutes and there will be a 6-minute
rest period between tasks.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
| Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
| Completed |
NCT04153006 -
Comparison of Fingerstick Versus Venous Sample for Troponin I.
|
||
| Completed |
NCT01205776 -
EXCEL Clinical Trial
|
N/A | |
| Active, not recruiting |
NCT04555174 -
BIOFLOW-VIII All-comers Orsiro Mission Safety and Performance Registry
|
||
| Recruiting |
NCT04582877 -
Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial
|
N/A | |
| Recruiting |
NCT04390672 -
Multivessel TALENT
|
N/A | |
| Recruiting |
NCT03265535 -
Validation of a Single Rest-Stress Imaging Protocol for Myocardial Perfusion Imaging
|
||
| Not yet recruiting |
NCT04522583 -
Increased CRP Concentrations in Patients Admitted to the Emergency Department With Troponin Elevation Aids to Rule Out Coronary Ischemia
|
||
| Terminated |
NCT02407626 -
Optimization of Cardioprotection in Diabetic Patients Undergoing Cardiac Surgery
|
N/A | |
| Completed |
NCT02554006 -
Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings
|
N/A | |
| Completed |
NCT02510547 -
Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial
|
Phase 4 | |
| Active, not recruiting |
NCT02189499 -
Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent
|
Phase 2 | |
| Completed |
NCT02264717 -
Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease
|
N/A | |
| Completed |
NCT02197065 -
Pilot Study of Atorvastatin for Orthopedic Surgery Patients
|
Phase 2 | |
| Recruiting |
NCT01681381 -
Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization
|
N/A | |
| Completed |
NCT01679886 -
Comparison of Rubidium PET and SPECT With CZT Crystals for Detection of Myocardial Ischemia in Overweighed Patients and Women
|
N/A | |
| Completed |
NCT01655043 -
Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI
|
Phase 2 | |
| Terminated |
NCT01892917 -
BIOFLOW-III Hungary Satellite Registry
|
N/A | |
| Completed |
NCT02707445 -
Genotyping Influences Outcome of Coronary Artery Stenting
|
N/A |